Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Phesgo with chemotherapy de-escalation in HER2-positive FUSCC HER2-CLA early breast cancer
ChiCTR2500109333Phase 4Not yet recruiting
- Sponsor
- Southwest Medical University
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of trastuzumab in breast cancer, sponsored by Southwest Medical University. Primary endpoint: tpCR in the MRI-responsive group. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2500109333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109333.